Navigation Links
Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
Date:5/20/2013

Boston, MA (PRWEB) May 20, 2013

Gilman Law LLP, a leading pharmacy law and defective drug plaintiffs’ law firm investigating Byetta lawsuits, is troubled by a new study that reveals that pancreatic cancer reports associated with Byetta and similar type 2 diabetes drugs are growing. The analysis, conducted by the Institute for Safe Medication Practices (ISMP), found that 71 Byetta pancreatic cancer reports had been made to the U.S. Food & Drug Administration (FDA) as of June 30, 2012. Overall, Byetta and other incretin mimetics were associated with 105 reports of pancreatic cancer and 831 reports of pancreatitis, a known risk factor for pancreatic cancer. The analysis appears in the ISMP’s April 2013 QuarterWatch report.

http://www.ismp.org/quarterwatch/pdfs/2012Q3.pdf

The defective drug and products liability law firm of Gilman Law LLP is providing free Byetta lawsuit consultations to individuals who have allegedly suffered serious side effects of the pancreas, including pancreatitis and pancreatic cancer. Potential claimants should be aware that Byetta lawsuits, like all personal injury claims, are subject to a strict statute of limitations that varies by state. To ensure that their right to recovery is not put in jeopardy, individuals seeking to file a Byetta lawsuit are urged to contact our defective drug lawyers today, TOLL FREE at 888-252-0048 or submit a free legal consultation form online.

Byetta and other incretin mimetics work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. In March 2013, the FDA announced it had launched a safety review of incretin mimetics, following a study that linked the drugs to high rates of hospitalization for pancreatitis, as well as precancerous lesions in the pancreas of patients who take the drugs. In addition to Byetta, the FDA was also investigating a number of other incretin mimetics, including Bydureon, Janumet, Janumet XR, Januvia, Juvisync, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, Tradjenta, and Victoza.
http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm

On April 5th, plaintiffs petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form a multidistrict litigation for all pending and future lawsuits filed on behalf of individuals who developed pancreatic cancer, allegedly due to the use of Byetta and other incretin mimetics. Oral Arguments on the matter are scheduled for May 30th. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL Pending No. 46 (JPML))
http://www.jpml.uscourts.gov/sites/jpml/files/Hearing_Order-5-30-13.pdf

Gilman Law LLP is providing complimentary lawsuit evaluations to users of Byetta and other incretin mimetics who developed pancreatitis or pancreatic cancer that may be associated with the use of these drugs. For more information, please contact Gilman Law LLP today by visiting our website to fill out a free, no obligation case evaluation form, or call Toll Free at 1-888-252-0048.

About Gilman Law LLP

Gilman Law LLP, a leading pharmaceutical law and defective drug law firm, has been recognized for delivering successful results to their clients across a broad range of claims stemming from consumer product injury, mass tort, and class action lawsuits. For over 33 years, the Gilman Law LLP team of highly experienced lawyers has earned renown for tireless work on behalf of their clients on many of today’s most challenging and important legal issues.

Contact:
Gilman Law LLP
Beachway Professional Center Tower
Suite 525-405
8951 Bonita Beach Road
Bonita Springs, FL 34135

Read the full story at http://www.prweb.com/releases/2013/5/prweb10736284.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
2. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
3. DrugRisk Announces Launch of Byetta Cancer Resource Center
4. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
5. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
6. Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
7. DrugRisk Update: Byetta Maker Agrees With Transferring Lawsuits to Federal Court
8. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
9. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Know The Symptoms Of A Failure And Offers To Name The Best Lawyers & Law Firms For Failure Victims
10. US Drug Watchdog Now Offers To Help Every Recipient Of A DePuy Pinnacle Or Recalled DePuy ASR Hip Implant Who Had To Go Through Revision Surgery Get To The Best Lawyers
11. LawyersandSettlements.com Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves ... to buy neoprene knee sleeves for lifting and any sport that requires ... on two main aspects to provide a higher quality knee sleeve performance. Firstly it ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... 2016 , ... Halfway through its partnership with First 5 LA, Western University ... than 15,900 children 5 years old and younger and treatment services to more than ... of five years to Western University of Health Sciences, UCLA and USC, beginning March ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)...  Wellbridge Health and Gateway Health proudly announce a dynamic ... and Medicaid plan members with specific high risk needs. ... of this group of consumers, Wellbridge combines technology and population ... insight into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... 2016 Eisai Inc. announced today new analyses ... Meeting of the American Epilepsy Society (AES). ... an adjunctive therapy for the treatment of partial onset ... primary generalized tonic-clonic seizures (PGTC) in patients with epilepsy ... see Important Safety Information for FYCOMPA, including Boxed WARNING ...
Breaking Medicine Technology: